Related Experiment Video
Updated: Jul 28, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Risk Stratification of Cardiovascular Disease according to Age Groups in New Prevention Guidelines: A Review
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.
Insights
Cardiovascular disease risk assessment requires tailored approaches for different age groups. While older adults may face risks from intensive treatments, younger individuals have high lifetime risks, necessitating balanced prevention strategies.
Area of Science:
- Cardiology
- Preventive Medicine
- Geriatrics
Background:
- Age is a significant risk factor for cardiovascular disease (CVD).
- Current CVD risk prediction models incorporate age as an independent factor.
- Effective management of CVD risk factors benefits older adults, but intensive treatments may increase adverse event risks.
Purpose of the Study:
- To evaluate age-specific cardiovascular disease prevention strategies.
- To address the balance between undertreatment in younger individuals and overtreatment in older adults.
- To incorporate lifetime risk and patient-specific factors into CVD prevention.
Main Methods:
- Review of the 2021 European Society of Cardiology guideline on CVD prevention.
- Analysis of age-dependent risk stratification and treatment recommendations.
- Consideration of factors beyond age, including comorbidities, frailty, and patient preferences.
Main Results:
- The 2021 ESC guideline proposes age-group-specific risk stratification and treatment recommendations.
- Intensive therapies in older adults (e.g., blood pressure, glucose lowering) can increase risks of adverse events like falls, syncope, and hypoglycemia.
- Younger individuals have low 10-year CVD risk but high lifetime risk, suggesting a need for early prevention considerations.
Conclusions:
- A balanced, individualized approach to CVD prevention is crucial for all age groups.
- Age-dependent risk stratification should guide, not mandate, treatment initiation.
- Factors such as lifetime risk, treatment benefits/harms, comorbidities, frailty, and patient preferences are essential for personalized primary prevention strategies.
Abstract:
Age is a strong risk factor for cardiovascular disease. Accordingly, most cardiovascular risk prediction models have included age as an independent risk factor. There is much evidence that effective management of cardiovascular risk factors improves clinical outcomes even in older adults. However, there are concerns that intensive treatment for older adults increases the risk of adverse events. For hypertensive patients, intensive blood pressure reduction with combination therapy increases the risk of syncope, acute kidney injury, and falls. Intensive glucose-lowering therapy among older patients with diabetes increases the risk of hypoglycemia or cognitive impairment. These findings suggest that a balanced approach for older adults is required to increase the benefits and decrease the risk of side effects. In contrast to older people, the estimated 10-year cardiovascular risk in young and healthy individuals is low. However, the lifetime cardiovascular risk in these patients is actually high. The 2021 European Society of Cardiology guideline on cardiovascular disease prevention in clinical practice has been published. It proposed a different risk stratification and recommendation for treatment according to age group, based on the concept of avoiding undertreatment in young people and overtreatment in older persons. Although the guideline recommends age-dependent risk stratification, risk categories should not be applied to the mandatory initiation of drug treatment. In all age groups, other factors such as lifetime cardiovascular risk, treatment benefit and harm, comorbidities, frailty, and patient preferences should be considered when managing patients for primary prevention.
More Related Videos
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Cardiovascular Drugs: Classification based on Therapeutic Indications
Atherosclerosis III: Management
Pre-Procedural Guidelines for Assessing Blood Pressure
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Heart Failure IV: Classification and Diagnostic Evaluation

